Clearmind patent publication covers Japan treatment for dyskinesia
Clearmind Medicine said a Japan patent application was published covering a 3-MMC-based treatment for dyskinesia, including combinations with palmitoylethanolamide (PEA).
Clearmind Medicine said a Japan patent application was published covering a 3-MMC-based treatment for dyskinesia, including combinations with palmitoylethanolamide (PEA).